Upadacitinib
As of the edition of 20 October 2026, Upadacitinib is a small molecule: marketed, first approved in 2019 (US); acts on JAK1, JAK2 and JAK3; US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Small molecule
- Brand name
- Rinvoq
- First approved
- 16 August 2019 (US)
- Approvals on record
- 20 in 5 regions
- Holder of the most recent approval
- AbbVie; 2 holders in all
- Registered trials
- 114, 6 stopped early
- Disease areas
- Skin and connective tissue; Immune system; Bones, joints and muscles; Digestive system; Inherited and neonatal; Heart and blood vessels
US protection
US protection ends in 2036.
The last listed US drug-substance patent ends in 2036. The application that gives this date is held by AbbVie.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product65 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 65 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Upadacitinib.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 21 | 5 | 11 | 1 |
| Phase 1 | 6 | 3 | 3 | 0 |
| Phase 2 | 21 | 12 | 8 | 1 |
| Phase 3 | 47 | 23 | 20 | 3 |
| Phase 4 | 19 | 2 | 15 | 1 |
| All trials | 114 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Originator, Applicant and Lead sponsor of trials | 2012 to now |